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A. Abbreviations  
CCHD -Congenital cyanotic heart disease 
CT -Closure times 
RCWMCH -Red Cross War Memorial Children’s Hospital  
PFA-Platelet function analyser  
CADP- Collagen/adenosine diphosphate 
CEPI- Collagen/epinephrine 
CPB-Cardio-pulmonary bypass 
RBC-Red blood cells 
ACT- Activated clotting time 
ABG- Arterial blood gas 
VWD-Von-Willebrand’s Disease  
GP-Glycoprotein 
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B. Protocol  
B1. Introduction 
B1.1 Purpose of the study 
To establish the median and interquartile range or the mean and standard deviation for closure 
times (CT) , with the CADP and CEPI cartridges for children with Congenital Cyanotic Heart 
Disease) CCHD and to compare this to normal children.  
 
B1. 2 Background 
Children with CCHD are known to have haemostatic deficiencies (Zabala and Guzzetta 2015). 
Mechanisms to explain platelet dysfunction were postulated by Horigome et al to be as a result 
of the production of microparticles by the platelets (Horigome, Hiramatsu et al. 2002). It is 
thought that the hypoxemia causes a secondary erythrocytosis which causes an increase in red 
cell mass and blood viscosity which in turn increases platelet microparticles resulting in 
decrease platelet production, increased activation and resultant thrombocytopenia (Zabala 
and Guzzetta 2015). The sheer stress due to viscosity also decreases platelet counts (Zabala 
and Guzzetta 2015). Further postulations include suppression of the thrombomodulin-protein 
C and protein S pathways as a result of erythrocytosis (Horigome, Murakami et al. 2003).   
Most normal paediatric coagulation parameters are highly dependent on age (Toulon, 
Berruyer et al. 2016). Pro-thrombin time is unchanged throughout childhood and similar to 
adults, whereas activated partial thromboplastin times are significantly longer in younger 
children  (Toulon, Berruyer et al. 2016). Antithrombin, protein c and protein s are significantly 
higher in younger children and reach adult levels by 1-5 years of age. All clotting factors expect 
factor 5 are lower in neonates and reach adult levels by the end of their first year. Factor 8 and 
von Willebrand’s are higher in younger children and reach normal values between 6-12 months 
of life (Toulon, Berruyer et al. 2016).   
Tests for platelet function have been used for over a century, the earliest being the bleeding 
time, an in vivo test. The bleeding time measures the time for cessation of bleeding from a 
wound. It has been criticized for being non-specific, insensitive, having high inter-operator 
variability, and frequent scar formation (Michelson 2004, Michelson, Cattaneo et al. 2005). The 
gold standard test was platelet aggregometry. This test measured platelet to platelet adhesion. 
It has also had a lot of criticism; it has poor reproducibility, high sample volume requirement 
for sample preparation, length of assay time, the requirement of a skilled technician, and high 
expense of the test (Michelson, Cattaneo et al. 2005). 
A newer test, known as the PFA, has been noted for its simplicity, rapidity and needing low 
sample volumes.  There is no sample preparation and whole blood can be used (Michelson, 
Frelinger et al. 2006).The test draws up whole blood through a 150 micro-meter diameter 
collagen coated aperture. The time to occlude the aperture is called the closure time (CT). This 
is done either in the presence of adenosine diphosphate (CADP) or epinephrine (CEPI) 
cartridges (Michelson 2009).Citrated whole blood (0. 8 ml) is required and testing must be 
done within 4-5 hours of sampling. Prolonged CTs with only the CEPI cartridge are observed 
with mild inherited platelet function disorders (e.g. storage pool disorders) and with aspirin 
ingestion, while prolonged CTs with both CEPI and CADP cartridges are found with more severe 
inherited platelet dysfunctions (Rand, Leung et al. 2003). 
 
 




Patients with CCHD often require definitive or palliative surgery for their structural problem. 
Often these surgical procedures require invasive surgical procedures requiring cardio-
pulmonary bypass (CPB). Red blood cells (RBC) are often used to prime the CPB circuit to 
accommodate for haemodilution. Coagulation products such as platelets and cryoprecipitate 
can often be used as prophylactic coagulation cover post CPB.  The PFA has been used to guide 
transfusions in another populations of patients requiring CPB. In patients undergoing aortic 
valve replacement a prolonged closure time has been observed (Sucker, Litmathe et al. 
2011).This prolonged closure time correlated with increased transfusion requirements. 
Coagulation factors and RBC are expensive commodities. Possibly, a simple easy test such as 
the PFA could guide transfusion requirements in this population, costs could be reduced, and 
transfusion risks reduced.  
 
B2.  Methodology 
B2.1 Study design 
This is to be a prospective observational study. A mean and standard deviation for the 
population group will be established.  
A comparison of PFA 100 closing times in patients with CCHD to healthy patient’s PFA 100 
closing times will be made. 
 
B2.2 Characteristics of the study population (n= 100) 
Inclusion criteria will be the following;  
Children from birth to 16 years old diagnosed with congenital cyanotic heart disease 
presenting for corrective or palliative cardiothoracic surgical procedures at Red Cross War 
Memorial Children’s Hospital (RCWMCH).  
1. Invasive arterial monitoring indicated 
2. Activated clotting time (ACT) monitoring and / or arterial blood gas (ABG) monitoring 
indicated  
3. No known bleeding diathesis   
4. No recent aspirin and clopidogrel ingestion 
5. No anaemia or thrombocytopenia present  
 
B2.3 Recruitment and enrollment 
RCWMCH has 3 full day (Monday, Tuesday and Wednesday) and two half day (Thursday and 
Friday) cardiothoracic lists. Eligible patients will be identified following pre-operative admission 
on the day prior to surgery in the cardiothoracic ward. After reading through a patient 
information form (appendix 1), written and verbal informed consent will be obtained from the 
parent or guardian, in their own language (appendix 1) for enrolment in the study. Blood 
sampling for the PFA 100 will occur the following day. We expect that approximately 2-3 
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children per week are eligible for this study. The study will run for approximately one year, in 
order to recruit approximately 100 patients.  
 
B2.4 Research procedures and data collection methods 
Following routine gas inhalation induction of the child, routine placement of invasive arterial 
blood pressure monitors will be established.  A routine ABG (1 ml), taken in a heparinized 
syringe, and an ACT (0, 5 ml) will be drawn.  
A further 0.8 ml of whole blood will be required by the PFA for each cartridge, a total of 1.6 ml.  
This however will be drawn and placed in a citrated tube which requires 2.3 ml of whole blood.  
The sample will be sampled within 4-5hours with the PFA 100. The intention is to move the 
PFA 100 analyzer to the RCWMCH, in order to eliminate the need for transport and storage of 
samples.  A CT will be determined with both CEPI and ADPI cartridges. These results will be 
recorded on the data collection sheet (appendix 2). This collection will run over approximately 
a year. 
 
B2.5 Data analysis 
Our primary outcome will be to report the CT as a mean and standard deviation for this 
population or a median and interquartile range depending on data distribution.  
The secondary outcome will be comparing the ranges of these patients with CCHD with the 
published results for healthy children, using an independent samples t-test. A p value of less 
than 0.05 will be considered significant. Pearson correlation with a 2 tailed test will be used for 
parametric data and the spearman correlation with a 2 tailed test for non-parametric data.   
The IBM SPSS v25 statistical software will be used. 
 
B3. Description of risks and benefits 
There are no risks involved in this study. The invasive lines and blood sampling are part of 
routine care for these patients during the procedure. The maximum amount of blood 
withdrawn at the given time will be 3,8 ml (2,3ml +0,5ml +1.0 ml). Children undergoing this 
type of major surgery for their pathology will be cross-matched and blood in theatre which will 
be used to prime the extra-corporal circulation, as well as for transfusion to the child. However, 
the additional amount of blood sampled for the study (2.3ml) is unlikely to result in transfusion.  
 
B4. Informed consent process 
On the day preceding the surgery written and verbal consent will be obtained from the parent 
or guardian of the patient in their own language. A translator will assist in the verbal process. 
A written consent and information form will be provided and contain information in layman 
terms. The guardian will be assured of the low risk for participation and allowed to withdraw 
consent to participate at any stage. If the guardian withdraws, they will be assured that the 
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B5. Privacy and confidentiality 
Each participant will receive a unique data collection identification number. All hard copies of 
data collection sheets will be kept in the Department of Anaesthesia and Perioperative 
Medicine in a locked cabinet of the Principal Investigator. Collated electronic data will be 
password protected.  
 
B6. Reimbursement for participation 
Participants will not receive any reimbursement for participation. If they consent to 
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C. Literature review  
Objectives of the literature review:  
The objective of the following was to review the current literature available concerning how 
platelets function and the modalities available to clinicians to  assess their function. The 
platelet function analyser was to be reviewed more extensively than the other modalities. The 
review also aims to compare it to the other modalities and to determine its clinical utility in 
common patient populations, such as obstetric and uremic patients,  and clinical settings such 
as cardiopulmonary bypass.  
Search strategy of the literature review:   
Google scholar was used to obtain articles. Terms such as “platelets” , “Platelet function 
analyser”, “Tests of platelet function”, “Platelet dysfunction” , “Platelet kinetics” were used to 
obtain articles. Articles relating to the objectives of the review were used and none were 
excluded on any basis. The majority are published from the 2000s however older articles were 
reviewed in conjunction. It is important to note that most of the literature is from the adult 
population.  
Review 
• Platelet Physiology 
Platelets originate from myeloid stem cells. Myeloid stem cells develop into megakaryoblasts 
and then megakaryocytes which then become platelets. Platelets are discoid shaped structures 
and are approximately 3.0 x 0.5 micrometers in dimension. The normal number of platelets is 
150-450 x 109 per liter of blood and circulate for approximately 10 days in the vascular system. 
They possess a multitude of functions (Machlus, Thon et al. 2014).  
Despite being commonly known for their role in primary hemostasis, they also contribute to 
host defense, thrombosis formation, vessel constriction, and are involved in repair and 
inflammation (Jenne, Urrutia et al. 2013). These blood components were discovered in the 19th 
century when, with real time microscopy, there was the ability to identify distinct corpuscles 
and see thrombi formation.  
Platelets are intricate structures. They have an outer membrane which links to the open 
canicular system. On the outer membrane are glycoproteins (GP), which act as receptors, as 
well as purinergic receptors. Internally, platelets have microtubules, mitochondria and 
glycogen and other metabolites.  They do not contain a nucleus. There are dense granules, 
alpha granules and lysosomal granules. The dense granules contain adeno-diphosphate (ADP)/ 
adeno-triphosphate (ATP), calcium and serotonin. The alpha granules contain p-selectin, 
platelet factor 4, platelet derived growth factor, fibronectin, von Willebrand’s factor (vWF), 
fibrinogen, coagulation factors 5 and 13.  
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A platelets role in coagulation appears complex. The coagulation cascade and the tissue-based 
model will not be extensively discussed here.  
There are three main steps in a platelet’s role in the process of primary homeostasis (Rand, 
Leung et al. 2003). 
adhesion (Platelet to endothelium)  
activation (secretion and morphology change)  
aggregation (platelet to platelet) 
Adhesion 
On the event of vessel wall injury, collagen and the sub-endothelial layers of the vessel are 
exposed. The GPs on the platelet surface, in particular;   
GP1b/IX/ V bind vWF and GPVI binds collagen and an integrin alpha 2, beta 1 also bind collagen. 
In summary; two receptors bind collagen on the endothelial surface, and one binds vWF.  
This adhesive process is usually prevented by nitric oxide (NO), prostacyclin and the enzyme 
CD39. Prostacyclin does this by binding to a g-coupled protein receptor on the platelet and 
thereby increasing cyclic adenosine monophosphate (AMP) and thereby increasing the 
Calcium concentration within the platelets, keeping them in their “resting state. “  
Activation 
ADP binds to the other type of receptor (purinergic receptor) P2Y12. This activates a G 
inhibitory protein which reduces cyclic AMP activity and causing calcium efflux, there by 
activating the platelet.  
Aggregation 
To review the adhesive process, the combination of collagen and GPVI further activates the 
platelet and increases thromboxane A2 production, which further reduces prostacyclin 
production and results in another GP activation; the GP IIb/IIIa activation. On activation the 
alpha and dense granules release their substances and platelets change shape from a discoid 
morphology to a structure with a central body and dendritic processes.  
The activated GP IIb/IIIa complex binds vWF and fibrinogen which is a rod like protein and this 
forms part of third component of the process, which is aggregation.  
• Indications for platelet function testing 
This is required for a number of reasons which are listed below (Harrison 2005); 
Screening for platelet dysfunction  
Screening platelet donors  
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Screening for non-accidental injury in minors  
Monitoring desmopressin therapy 
Monitoring vWF replacement in vWF disease 
Monitoring pro-hemostatic therapy, when factor VIIa and platelets concentrates are used 
Monitoring anti-platelet therapy  
Detect drug resistance to drugs such as aspirin or clopidogrel  
Detect platelet hyperfunction  
Predicting surgical bleeding  
Testing the quality control of platelet concentrates  
• Available Tests  
Several tests for platelet function have been developed, these include the bleeding time, 
platelet aggregometry and a number of others are also available.   
The first in vivo test was called the bleeding time, and this was the most commonly used unti l 
the 1990s. With a proximal forearm blood pressure cuff inflated to 40 mmHg used, a distal 
surgical incision 10mm in length and 1mm in depth to the skin on the volar aspect of the 
forearm was made and the time to stop bleeding was recorded.  Normal range was between 2 
to 10 mins and severe pathology could result in bleeding times over 30 mins. This is a simple 
test, but evidently invasive, insensitive and time consuming (Dukc 1960).  
In the 1960s the gold standard test called platelet aggregometry was developed. This uses 
impedance technology. Citrated whole blood is centrifuged, and platelet rich plasma is 
obtained. 0, 5 ml of platelet rich plasma is required at 37-degree Celsius. Agonists such as ADP, 
collagen, thrombin, ristocetin, Adrenalin are added. These cause platelet aggregation. As 
platelets aggregate light transmission through the platelet rich plasma increases.  
A PFA is a relatively simple bench top instrument that simulates high shear platelet function 
within disposable test cartridges. Citrated whole blood is aspirated under constant negative 
pressure from the sample reservoir through a capillary and a microscopic aperture cut into a 
membrane.  
The membrane is coated with either collagen/epinephrine (CEPI) or collagen/ADP (CADP). 
These coatings are platelet activators. 
The presence of these platelet activators and the high shear rates (5000–6000m/ s 1) under 
the standardized conditions result in platelet adhesion, activation and aggregation resulting in 
formation of a platelet plug within the aperture. 
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Platelet function is thus measured as a function of the time it takes to occlude the aperture, a 
CT.   
The test is simple to perform, rapid with a maximal CT of 300 s and can test relatively small 
volumes (0.8 ml/cartridge) of citrated whole blood up to 4-5 hours from sampling. A time of 
over 300 s is reported as non-closure.  
There are a number of other new platelet function tests which are listed below; 
The cone and plate(let) analyzer test (IMPACT)  
Ultegra  
Hemostasis analysis system  
Platelet works 
Platelet flow cytometry  
• Role of thromboelastography (TEG) in the evaluation of platelet function  
Traditionally a TEG has been used in a trauma setting to monitor trauma induced coagulopathy 
(Walsh, Thomas et al. 2011). In patients that have a massive haemorrhage and goal directed 
blood component therapy required, a TEG can be helpful. A maximum amplitude that is 
decreased could indicate the need for platelet therapy (Walsh, Thomas et al. 2011).  
ROTEM and TEG have been investigated as a point if care test in cyanotic heart disease 
(Bhardwaj, Malhotra et al. 2017). A TEG was shown to have a prolonged k time and a decreased 
alpha angle in this population. The EXTEM and the INTEM was deranged in 87 % and 73% 
patients respectively.  
Interestingly  in an obstetric related study, the maximum amplitude of the TEG was compared 
to the CT of PFA in healthy pregnant women as well as pregnant women with both mild and 
severe pre-eclampsia (Davies, Fernando et al. 2007). It is known that severe pre-eclampsia is 
known to have a greater incidence of thrombocytopenia (Sharma, Philip et al. 1999).  
Often the presence of pre-eclampsia can influence the decision to perform a neuro-axial 
procedure or not.  In the study by Davies et el, 93 pregnant women were recruited, 50 of which 
who had either mild or severe pre-eclampsia, the remaining 43 were used as controls. The 50 
ladies with pre-eclampsia had absolute platelet counts which were lower. The maximum 
amplitude did not vary between the controls and the women with severe and mild pre-
eclampsia. However, the CT in the pre-eclampsia women were progressively prolonged when 
compared to the controls.  
 
• Clinical utility of the PFA 
Currently the PFA is considered as a primary hemostatic screening and not a diagnostic tool. 
 
 
Platelet function analyzer closure times in children with congenital cyanotic heart disease- A prospective observational pilot study 
 
13 
In the paediatric population the PFA could be potentially used as a screening tool for both 
Glanzmann’s Thrombocytopenia and detecting Von-Willebrand’s Disease (VWD) where both 
the closure times for the CADP and CEPI will be grossly prolonged (Harrison 2005). 
Unfortunately, the closure times in screening for either hemophilia A or B in children will not 
be of any benefit. However it could also possibly have utility to rule out non-accidental injury 
when there could be a primary platelet dysfunction (Harrison 2005).  
The PFA has the potential to monitor desmopressin (DDVAP) therapy for those with VWD 
(Favaloro 2008).  The PFA has also been used in monitoring aspirin therapy and detecting 
resistance, The CEPI in aspirin therapy will be prolonged and the  CADP will have a normal 
closure time (Favaloro 2008).  
It is important to note that low platelet counts (< 100 X 109, low hematocrit (< 20 %) also may 
cause prolongation of closure times (Harrison, Mackie et al. 2011).  
The PFA  will not be able to pick up disorders of fibrinogen and coagulation factors such as VIII, 
IX and X1 (Favaloro 2008) as mentioned above. Vitamin K antagonists as well as heparin also 
have minimal effects on closure time (Favaloro 2008). 
The PFA has been investigated with regards to predicting surgical bleeding, mainly in relation 
to cardiac surgery. It is sensitive to hemodilution, but authors believe bleeding is more related 
to surgical success and patient’s hemostatic status which should be assessed by family and 
personal bleeding history pre-operatively (Favaloro 2008). There is also this potential in 
paediatric patients coming for cardiac surgery (Harrison 2005).  
There is also further investigation needed as to whether shortened closure times are predictors 
of thrombosis risk, conclusions are yet to be drawn (Favaloro 2008). 
• PFA vs other platelet function tests 
The PFA is a fairly new test when compared with more classical platelet function tests such as 
a bleeding time. It has been noted that the PFA is as sensitive and reproducible in identifying 
the effects of aspirin when compared with a bleeding time. (Marshall, Williams et al. 1997)  
Marshall et el did a double-blinded randomized control trial that set out to look at drug 
monitoring with the bleeding time; the long-accepted method versus the PFA. 
Healthy males were randomized into receiving 750 mg of aspirin or placebo. Both the placebo 
group and the aspirin group had a bleeding time and a closure time performed, and it was 
concluded both bleeding time and closure time could identify effects of aspirin significantly 
when compared to the placebo group.  
It is also been suggested that PFA test may be a less invasive alternative to the bleeding time 
in the diagnosis and therapeutic monitoring of patients with platelet secretion defects 
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The PFA was  compared to platelet aggregometry in the pregnant women, 14 who were 
normotensive and 16 who had pregnancy induced hypertension  (Marietta, Castelli et al. 2001).  
A baseline CT and platelet aggregometry was done on the blood samples from the pregnant 
patients. Then, L-Arginine, which is part of the nitric oxide pathway and regulates the platelet 
pathway, was added to repeated samples and a repeat platelet aggregometry and CT were 
done. The aggregometry failed to demonstrate any difference between the hypertensive and 
normotensive women with the addition of L-arginine, whereas the CT was significantly altered.  
It was hypothesized in this study that the PFA CT can pick up subtle differences in platelet 
function that the traditional method could not.  
Uremia and cirrhosis  
Bleeding, noted in both uremia (Di Minno, Martinez et al. 1985) and liver cirrhosis  (Thomas, 
Ream et al. 1967), is a complex multifactorial complication in these conditions and can in part 
be attributed to platelet dysfunction, how they interact with each other and to the vessel wall.   
It is postulated that rheology of blood can affect the function of the platelets (Turitto and 
Baumgartner 1975) and that by improving the hematocrit the platelets can work in a more 
effective manner. 
Platelet aggregometry and CTs were done on 20 control patients, 21 patients with end stage 
renal disease and 20 patients with cirrhosis (Escolar, Cases et al. 1999). In the uremic and the 
patients with cirrhosis the CTs were prolonged significantly when compared to the controls. 
The aggregometry also picked up this platelet dysfunction. However, when the hematocrit was 
improved, the closure times also improved however the aggregometry was unaltered.  
This suggested that the PFA is a more sensitive test when hematocrit plays a role in uremic and 
cirrhosis related platelet dysfunction.  
However, in another single centre prospective pilot study the PFA was considered as a poor 
predictor of skin bleeding time whereas platelet aggregometry predicted the SBT better (Ho, 
Gemmell et al. 2008). There were multiple limitations in this study.  
PFA role in coronary artery bypass  
With the use of an extra-corporal circuit such as when cardio-pulmonary bypass (CPB) is 
required, a coagulopathy can result (Paparella, Brister et al. 2004).  
This can be a result of consumptive mechanisms, hemodilution, platelet losses as well as 
heparin and hypothermia, additionally contact with the foreign circuit can activate the cell-
based coagulation model. Fibrinolysis and primary platelet dysfunction can also occur.  
Raman et el report on 98 patients who had coronary artery bypass grafting (CABG) done, 36 
patients bled post-operatively and were treated empirically with platelet therapy. 16 were 
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classified as platelet responders and 20 as non-responders. Platelet counts alone were unable 
to predict this, however closure times which were done before heparinization and 15 minutes 
after reversal with protamine were reported as being 94% sensitive and 85% specific for 
predicting which patients would have responded to platelet therapy and those who would 
have not.  (Raman and Silverman 2001).  
• Normal Ranges for closure times  
A 1998 publication established closing time ranges for both CEPI and CADP cartridges for 
healthy children and neonates. Values reported are means ± 1 standard deviation (SD). The 
table below shows the results.  
 
Table 2 : PFA-100® closure times in healthy children and neonates.(Carcao, Blanchette et al. 1998) 




(x109 / l) * 
CEPI * CADP * 
Heathy 
children  









91 ± 13 (72-111)  
Healthy 
neonates  
17 >37 weeks 






81 ± 17t (61-
108)  
56 ± 6^(48-65)  
* Ranges in parentheses (minimum and maximum values). ^ Significantly different compared with children 
(combined data). P < 0-01.  
 
The typical normal ranges obtained with 3.2% trisodium citrate ; 55–112 s for CADP and 79–
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D. Manuscript  
D1. Abstract  
Objectives: To establish the median and interquartile range or the mean and standard 
deviation for closure times , with the CADP and CEPI cartridges for children with CCHD and 
to compare this to normal children.  
Design: Prospective observational pilot study 
Setting: Red Cross War Memorial Children's Hospital (RCWMCH) in association with the 
University of Cape Town 
Participants: Children between birth and 16 years old diagnosed with CCHD presenting for 
corrective or palliative cardiothoracic surgical procedures 
Interventions: 0.8ml of whole blood obtained from the participants was pipetted into both 
the CEPI and CADP cartridges and analyzed by the PFA machine.  Closure times for both 
cartridges were obtained and recorded on the data collection form.  
Results: 40 successful CADP samples and 39 successful CEPI cartridges were analysed. Of 
the total 40 valid CADP samples there was left skewed distribution , the median was 114.50 
seconds with an interquartile range  from 87.25 seconds to 153.75 seconds. Of the total 39 
valid CEPI samples the data was normally distributed to give a mean of 175.38 and a 
standard deviation of 74.998. Both of which are not significantly different from the typical 
normal ranges obtained with 3.2% trisodium citrate ; 55–112 s for CADP and 79–164 s for 
CEPI  (Harrison 2005). However, when compared to the normal ranges quoted by Carcao 
et al for neonates and children, there was a significant prolongation for both the CEPI and 
CADP samples in the neonates and children with CCHD 
Conclusion: This is a pilot study and limited by small sample sizes obtained due to time 
limitation. Further research would be needed to further assess whether the PFA could be 
used to guide platelet replacement in this population.  
D2. Aim  
The primary aim was to establish the median and interquartile range or the mean and 
standard deviation for closure times , with the CADP and CEPI cartridges for children with 
CCHD.  
The secondary aim was to compare this to normal children.  
D3. Methods  
This was a prospective observational pilot study conducted at Red Cross War Memorial 
Children's Hospital (RCWMCH) in association with the University of Cape Town. Ethical 
approval was obtained by the human research ethics committee at the University of Cape 
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Town, Ref 555/2017. The data collection ran from December 2017- September 2018 over 
a 10-month period. The study was time limited to a 10-month period.  
Children between birth and 16 years of age diagnosed with CCHD presenting for corrective 
or palliative cardiothoracic surgical procedures were recruited, the following were met for 
inclusion;  
Invasive arterial monitoring indicated 
Activated clotting time (ACT) monitoring and / or arterial blood gas (ABG) monitoring 
indicated  
No known bleeding diathesis   
No recent aspirin and clopidogrel ingestion 
No anaemia or thrombocytopenia present  
RCWMCH has 3 full day (Monday, Tuesday and Wednesday) and two half day (Thursday 
and Friday) cardiothoracic surgical lists. Eligible patients were identified following pre-
operative admission on the day prior to surgery in the cardiothoracic ward, by the 
anaesthetic registrar allocated to the cardiothoracic list the following day. Written 
(appendix 1) and verbal consent was obtained from the parent/ guardian and an 
information form (appendix 2) was supplied to the parent to read. Assent was obtained 
from the child if over 12 years of age (appendix 3).  
Following routine gas inhalation induction of the child, routine placement of an invasive 
arterial blood pressure monitor was established.  A routine ACT (0, 5 ml) and ABG (1 ml) 
were drawn. A further 2,3 ml of whole blood was drawn and placed in a citrated blood 
collection tube. This was marked with a unique anonymous patient identification number 
to match the data collection form as to ensure confidentially. The collected specimen was 
then transported with the data collection form to Groote Schuur Hospital.  
0.8ml of whole blood was pipetted into both the CEPI and CADP cartridges and analyzed 
by the PFA machine.  Closure times for both cartridges were obtained and recorded on the 
data collection form.  
A quality control check was run on the PFA prior to each sample being analyzed. A 5-hour 
interval from collection to analysis was allowed.  
Data was stored anonymously in a file in the laboratory at the Department of Anaesthesia 
and peri-operative medicine as well as in a password protected Drobox account.  
The results were analyzed with the IBM SPSS v25 statistical software. The results were 
reported as mean +_SD or median (IQR) 
The secondary outcome was comparing the ranges of these patients with CCHD with the 
published results for healthy children, using an independent samples t-test. A p value of 
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D4. Results  
Over a 10 month period there were a total of 62 patients with CCHD presenting for 
corrective or palliative cardiothoracic surgery at RCWMCH. A total of 55 patients were 
recruited for enrolment in the study and only 49 specimens run through the PFA.  
7 patients were not recruited for various reasons and 6 were recruited but not run through 
the PFA (Table 1).  
9 of the specimens run through the CADP cartridges and 10 of the specimens run through 
the CEPI failed due to technical reasons with the PFA.  
Of the 49 patients, cyanotic pathologies included 43 % Tetralogy of Fallot, 21 % had 
transposition of great vessels, 12 % had pulmonary atresia, 10 % had a double outlet right 
ventricle, 8 % had tricuspid atresia and 6% had other pathology (Chart 1).  
Chart 1: Percentages of cyanotic pathologies of total number of specimens run (n=49) 
 
 
Table 1: Patients not recruited  
Reason for not recruiting (n=7) Number  
Patient not identified pre-operatively 5 
Parent refused consent 1 
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Recruited, but specimen not run through 
cartridges (n=6) 
Number 
Specimen placed in incorrect sample tube 1 
Specimen arrived at GSH greater than 5 
hours post sampling 
2 
Specimen forgot to be run by receiving 
person 
1 
Patient recruited but specimen not taken 
due to busy theatre and complicated patient  
1 
No one available to transport specimen  1 
 
With regards to pre-operative haematological values  such as haemoglobin, platelets and 
ACT , these were all normally distributed. The mean haemoglobin was 15.4 +_2.6, the mean 
platelets was 359.9 +_134.0, the mean ACT was 124.9 +_ 20.8. There was no correlation 
between these pre-operative haematological values and the closure times of the CADP and 
the CEPI samples (Table 2).  
Table 2: Pre-operative Haematological values  
 n Hb (g/dl)1 Platelets (x109/l)1 ACT (seconds)1 
Total  40 15.4 +-2.6 359.9+-134.0 124.9+-20.8 
1.result reported as mean and standard deviation  
This resulted in 40 successful CADP samples and 39 successful CEPI cartridges analysed.  .  
Results according to neonates  
There were a total of 8 neonates (0-4 weeks) recruited. 8 successful CADP samples and 7 
successful CEPI samples.  
The mean and standard deviation for the CADP were 105 +_28. When compared to the 
normal for this age (Carcao, Blanchette et al. 1998) The difference is significant of -49.1, 95 
% CI: -63.7 -to -34.6 with a p value of <0.0001.  
The mean and standard deviation for the CEPI were 179 +_ 74. When compared to normal 
for this age (Carcao, Blanchette et al. 1998) the difference is significant -98.6 with a 95 % 
CI of -137.3 to -59.9 and p value < 0.0001. 
Results according to infants  
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 There were a total of 27 infants (4weeks-4 years) with successful samples. The median 
value and interquartile range for the CADP sample was 115 (86 – 150)respectively. The CEPI 
mean was 169 +_ 74. There was no comparative data for comparison analysis in this age. 
Results according to children  
There were a total of 5 children age ( 4-16  years) successful samples with both the CADP 
and the CEPI.   
The mean and standard deviation and standard deviation for the CADP was 170 +_72. There 
was a significant difference of -78.8 when compared to normal for this age, with 95% CI of 
-100.1 to -57.5 p value < 0.000.1.  
The mean and standard deviation for the for the CEPI were 206 +_ 88. There was a 
significant difference of -88.8 with a CI of -119.8 to -57.8 with P value < 0.0001 (Table 3) 
Table 3: Results according to age  
 n CADP(seconds) Difference to normal for age 6 
(Carcao, Blanchette et al. 1998) 
CEPI (seconds)1 Difference to normal for age 6 
Neonates  
0-4 weeks 
8 1051 +- 28 -49.130     
        
95 % CI: -63.7 -to -34.6   
p value <0.0001 
1794  +-74 -98.6  
 
95 % CI of -137.3 to -59.9 




27 115 3    
IQR(86 – 150)  




5 1701  +-72 -78.8       
      
95% CI of -100.1 to -57.5  
p value < 0.0001 
206  +-88 -88.8     
 
95% CI of -119.8 to -57.8  
P value < 0.0001 
1.result reported as mean and standard deviation 2. n=39 3. reported median as and interquartile range 4. n=7. 6 (Carcao, Blanchette et al. 1998) 
Results for the whole cohort  
Of the total 40 valid CADP samples there was left skewed distribution , the median was 114 
seconds IQR(87 -154).  
Of the total 39 valid CEPI samples the data was normally distributed to give a mean of 175 
+_ 75 seconds.  
Both of which are not significantly different from the typical normal ranges obtained with 
3.2% trisodium citrate ; 55–112 s for CADP and 79–164 s for CEPI  (Harrison 2005), 
according to Oxford Hemophilia Centre, 2002 normal range (Table 4) 
Table 4: Results of entire cohort  
Total CEPI  (seconds)1 Difference5 Total  CADP (seconds)3 Difference5 
n=40 1752  +-75 Nil significant n=39 114 IQR(87 -154) 
 
Nil significant 
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D6. Discussion  
The study was able to establish either the mean and standard deviation or the median and 
interquartile range for both the CEPI and CADP for children with CCHD. When comparing the 
total sample recruited in the study to the normal range for closure times, there was no 
significant difference. However, when the total sample recruited was divided into neonates 
and children both CEPI and CADP closure times were significantly prolonged when compared 
to the normal for age.  
The research is novel, there is no prior closure time evaluation been performed on children 
with CCHD. Other populations known to have platelet dysfunction have been investigated, 
however children with CCHD however, almost exclusively, have not had their closure times 
performed until this pilot.  
As discussed in the protocol background , it is thought that the hypoxemia causes a secondary 
erythrocytosis which is an increase in red cell mass and blood viscosity which in turn increases 
platelet microparticles resulting in decrease platelet production, increased activation and 
resultant thrombocytopenia (Zabala and Guzzetta 2015). It could be postulated that these 
abnormalities with platelet function seen in CCHD are actually able to be identified by the PFA 
and thereby causing prolonged closure times, as seen by the cohort in this pilot.  
 
This prolongation of the closure times noted in this cohort echoes the similar haemostatic 
deficiencies that have been noted by TEG and ROTEM in previous studies  (Bhardwaj, Malhotra 
et al. 2017).  
 
The study is an observational pilot study so sample size is limited, mainly due to time 
constraints, which is the biggest limitation of the study. Unfortunately the investigators could 
not calculate what an adequate sample size for recruitment would be. There is limited data 
available regarding the normal closure times for children without pathology. The data available 
also only indicates normal closure times for neonates and children and excludes infants so 
makes a comparison in this age group not possible. In future studies possible recruitment of 
children without CCHD for control measurements would be of benefit.  
However, even though sample sizing in the study was an obstacle, a strength of the study is 
that over a 10 month period there were 62 possible candidates to recruit and subsequently 40 
successful CADP cartridges and 39 successful CEPI cartridges analysed, which is 64 % and 62 % 
respectively, which in the investigators opinion was a good total number if one was to 
postulate that the 62 candidates could actually be said to be a population , i.e. the amount of 
children with CCHD needing surgery at RCWMCH over a certain time period, and the number 
of successful cartridges, the sample.  
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It would be highly beneficial if further research could perform more closure times on healthy 
children so get a more reliable control for comparison and especially to establish the range of 
closure times for infants, as this is the largest portion of this study sample size.  
If the results of this study had neglected to show any prolongation in closure time in children 
with CCHD, the PFA could be placed aside as an insignificant investigation in this population. 
Even though sample sizing is a problem, there is noted to be significant prolongation in  closure 
times, so this follows that this investigation needs to be deemed whether clinically it has a role 
and whether that role is actually clinically beneficial or not. Further research would be 
suggested to follow this theme.  
A similar study to the one by Raman et al, in which the PFA was used to predict platelet 
responders and platelet non-responders post CABG done on CPB bleeding, would be 
interesting to perform on children with CCHD who get empirically treated with platelets for 
bleeding peri-operatively. This would be a landmark to ascertain whether each child with CCHD 
should have a routine PFA done to better guide the use coagulation products.   
D7. Conclusion 
Congenital cardiac disease is a common presentation of congenital diseases in neonates, 
infants and children. Certainly the cyanotic sub-type being less common. However,  the disease 
entity can be the cause of significant morbidity and mortality. As a discipline of anaesthetists 
we are aware of the risks as well as costs of the use of blood products and have seen benefit 
of using a guide to transfusion with tests such as TEG. Proposed guidance with a test such as  
a PFA in the transfusion of platelets in this population of paediatrics may seem a far off 
concept. However due to this observational pilot study and the noted prolongation of closure 
times in neonates and the children it cannot be ignored that this proposed guidance of platelet 
transfusion despite the evidence being in it’s infancy.  
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F. Appendices  
F1. Consent form  
Platelet function analyzer (PFA) 100 closing times in children with congenital cyanotic heart disease  
An observational study: Consent form 
 




Participation of child in platelet function analyzer (PFA) 100 closing times in children with congenital cyanotic 
heart disease: An observational study 
 
     
 Please initial black box or thumbprint 
6. I confirm that I have read and understood the contents of the information 
form presented to me.  I confirm that I have had an opportunity to  
consider the contents of the information sheet and to ask any question freely. 
I confirm that these questions have been answered clearly and that I am  
satisfied with the explanation that I have received. 
 
2. I agree that my child’s participation in this study is voluntary.  I understand that I  
may freely withdraw my child from this study at any point prior to any medication 
being given in theatre, without having to give any reason for the withdrawal;  
and that the withdrawal will not affect my medical care. 
 
3. I agree for my child to take part in this study and understand that approximately 3,6 ml of blood will be taken.  
 
 
                                                                                                         




                                         




                                                                                                      
Name of witness                 Signature    Date 
 
If you have any questions about this study, please contact one of the investigators: 
Dr LJ Kempe laura_kempe@yahoo.com 
Dr G Wilson  graeme.wilson@uct.ac.za 
Questions regarding your rights as a volunteer may be addressed to the Research Ethics Committee 
University of Cape Town that reviewed the ethical aspects of this study at 021 406 6492. Room 52-24, 
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F2. Information form  
Platelet function analyzer (PFA) 100 closing times in children with congenital cyanotic heart disease  
An observational study - Information form 
 
We have noted that your child has heart disease. Only a small portion of their blood is able to reach their 
lungs and pick up oxygen.  As a result, they sometimes look slightly blue.  
 
Their blood is made up of three main parts; the red blood cells which carry oxygen, the white blood cells 
which help to fight infection. The third part are platelets. Platelets are important for forming a blood clot if 
there is bleeding.  
 
Sometimes, the platelets don't work exactly as they should if a patient has heart disease.  
 
It is possible to do a blood test called a full blood count to see how many platelets are in the blood. However, 
this test doesn't show how well the platelets are working. We have other tests that show us how well they 
are working. 
 
There is a fairly new blood test called the platelet function analyzer (PFA 100). This test sucks up blood 
through a small hole and the time to close that hole with a blood clot is called a “closing time”.  
 
The aim of this study is to see whether the closing times of patients with heart disease are different to those 
without heart disease.  
 
Your child is going for a surgery and will get a type of drip put into a blood vessel to monitor the blood 
pressure throughout the surgery.  This will be done even despite the study. From this drip, blood is going to 
be taken to monitor how the child is coping during the surgery. This will also be done despite the study.  
 
We want to request that we can take an additional amount of blood (3,6 ml) at this time. The amount we 
need is very small and won’t affect the child.  
 
This blood sample will then be tested on the platelet function analyzer test.  
 
The risks are no greater than those of the routine procedure that is taking place. It is an observational study 
so nothing extra is being done.  
 
You will not receive any form of payment for having your child participating in this study.  Participation is 
completely voluntary. You may withdraw from this study at any point, without influencing your child’s 
treatment. 
 
All the results of the study will be private  
You are welcome to contact the study leaders with any questions at any stage;  
Dr LJ Kempe laura_kempe@yahoo.com 
Dr G Wilson  graeme.wilson@uct.ac.za  
 
Questions regarding your rights as a volunteer may be addressed to the Research Ethics Committee 
University of Cape Town that reviewed the ethical aspects of this study at 021 406 6492. Room 52-24, Old 
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F3. Assent form  
Platelet function analyzer (PFA) 100 closing times in children with congenital cyanotic heart disease  
An observational study: Assent form 
 
 




My own participation in platelet function analyzer (PFA) 100 closing times in children with congenital cyanotic 
heart disease: An observational study 
 
I understand that I am going for an operation on my heart, as I have a heart disease that I was born with.  
 
I understand that the doctors need to take routine blood tests when I am asleep, this is done through a type 
of drip in my blood vessel, that will be inserted as a routine part of my operation.  
 
When they take these routine blood tests, I give my permission for them to take an extra 3.6 ml of blood for 
a test that looks at how well my platelets are working.  
 
Platelets are small parts of the blood that help with making a blood clot if I bleed.  
 
I understand that there are no risks involved for me, no more than routine care.  
 
I understand that this study will not hurt me or cause me problems in any way.  
 
I understand that I can choose not to be involved in the study at any time, without it affecting my care.  
 
I understand that my parents also know about the study and are happy to allow me to be involved.  
 
I understand that if I participate it may help children in the future who are having a similar operation.  
 
I will volunteer to participate in this study. 
 
 
My Name:  
 
My Signature:  
 




If you have any questions about this study, please contact one of the investigators: 
 
Dr LJ Kempe laura_kempe@yahoo.com or Dr G Wilson  graeme.wilson@uct.ac.za 
 
Questions regarding your rights as a volunteer may be addressed to the Research Ethics Committee 
University of Cape Town that reviewed the ethical aspects of this study at 021 406 6492. Room 52-24, Old 
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F4. Data collection form  
Platelet function analyzer (PFA) 100 closing times in children with congenital cyanotic heart disease  
An observational study: Data collection form  
 
 
Unique patient identification number:  
 
Date and time of collection: 
 






Type of cyanotic pathology:  
 




Pre-operative platelet count:  
 
Baseline ACT:     
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F5. Ethics approval letter 
Signature Removed
